Phase 2 trial of sustained-release fampridine in chronic spinal cord injury

Spinal Cord

Volumn 45, Issue 2, 2007, Pages 158-168

  Cardenas, D D ^a   Ditunno, J ^b   Graziani, V ^b   Jackson, A B ^c   Lammertse, D ^d   Potter, P ^e   Sipski, M ^c   Cohen, R ^f   Blight, A R ^f  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c University of Alabama at Birmingham   (United States)

^d CRAIG HOSPITAL   (United States)

^e ST JOSEPH S HEALTH CENTRE   (Canada)

^f ACORDA THERAPEUTICS INC   (United States)

Author keywords

4 aminopyridine; Erectile function; Questionnaires; Randomized trial; Spasticity

Indexed keywords

4 AMINOPYRIDINE; CARBAMAZEPINE; FAMOTIDINE; PHENYTOIN; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ANXIETY; ARTICLE; ASTHENIA; BACKACHE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ELECTROCARDIOGRAM; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE HYPERTONIA; MUSCLE SPASM; NAUSEA; NERVOUSNESS; OUTCOME ASSESSMENT; PAIN; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SEIZURE; SIDE EFFECT; SPASTICITY; SPINAL CORD INJURY; SUSTAINED DRUG RELEASE; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; URINARY TRACT INFECTION; VITAL SIGN;

4-AMINOPYRIDINE; ADULT; AGED; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; POTASSIUM CHANNEL BLOCKERS; SPINAL CORD INJURIES; TREATMENT OUTCOME;

EID: 33846834028     PISSN: 13624393     EISSN: 14765624     Source Type: Journal    
DOI: 10.1038/sj.sc.3101947     Document Type: Article

References (23)

1. Blight AR. Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res Bull 1989; 22: 47-52.
2. Waxman SG. Aminopyridines and the treatment of spinal cord injury. J Neurotrauma 1993; 10: 19-24.
3. Potter PJ et al. Randomized double-blind crossover trial of Fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury. J Neurotrauma 1998; 15: 837-849.
4. Hayes KC et al. Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury. Paraplegia 1993; 31: 216-224.
5. Hansebout RR, Blight AR, Fawcett S, Reddy K. 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients. J Neurotrauma 1993; 10: 1-18.
6. Hayes KC et al. 4-Aminopyridine-sensitive neurologic deficits in patients with spinal cord injury. J Neurotrauma 1994; 11: 433-446.
7. Potter PJ et al. Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: three cases. Spinal Cord 1998; 36: 147-155.
8. Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1990; 27: 186-192.
9. Jones RE et al. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 1983; 60: 353-362.
10. Sanders DB, Kim YI, Howard Jr JF, Goetsch CA. Eaton-Lambert syndrome: a clinical and electrophysiological study of a patient treated with 4-aminopyridine. J Neurol Neurosurg Psychiatry 1980; 43: 978-985.
11. Stefoski D et al. 4-Aminopyridine in multiple sclerosis: prolonged administration. Neurology 1991; 41: 1344-1348.
12. Bever Jr CT et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 1994; 44: 1054-1059.
13. Ball AP et al. Human botulism caused by Clostridium botulinum type E: the Birmingham outbreak. Q J Med 1979; 48: 473-491.
14. Murray NM, Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 1981; 31: 265-271.
15. Spyker DA, Lynch C, Shabanowitz J, Sinn JA. Poisoning with 4-aminopyridine: report of three cases. Clin Toxicol 1980; 16: 487-497.
16. Evenhuis J et al. Pharmacokinetics of 4-aminopyridine in human volunteers. A preliminary study using a new GLC method for its estimation. Br J Anaesth 1981; 53: 567-570.
17. Hayes KC et al. Pharmacokinetics of an immediate release oral formulation of fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J Clin Pharmacol 2003; 43: 379-385.
18. Hayes KC et al. Pharmacokinetic studies of single and multiple oral doses of Fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injury. Clin Neuropharmacol 2003; 26: 185-192.
19. Rosen RC et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830.
20. American Spinal Injury Association (ASIA). Standards for Neurological Classification of Spinal Injury Patients (revised 1996).
21. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540-542.
22. Hayes KC et al. Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. Arch Phys Med Rehabil 2004; 85: 29-34.
23. Schuele SU et al. Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen. Neurology 2005; 64: 1086-1087.